Trial Search Results

Autologous Bone Marrow Transplantation in Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission

Evaluate the role of high dose chemotherapy with autologous hematopoietic cell transplantation for AML.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Procedure: high dose chemotherapy then autologous hematopoietic cell transplant


Phase 2


Inclusion Criteria:- must be in remission

   - adequate organ function Exclusion Criteria:- prior MDS

   - active infection

   - liver disease

Ages Eligible for Study

16 Years - 69 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
BMT Referrals